Compare SCI & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCI | MDGL |
|---|---|---|
| Founded | 1962 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 11.1B |
| IPO Year | 1994 | 2005 |
| Metric | SCI | MDGL |
|---|---|---|
| Price | $75.14 | $525.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $98.00 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 1.8M | 275.2K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | 7.65 | ★ 41.32 |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $4,309,234,000.00 | $180,133,000.00 |
| Revenue This Year | $4.03 | $58.39 |
| Revenue Next Year | $3.73 | $48.55 |
| P/E Ratio | $74.97 | ★ N/A |
| Revenue Growth | ★ 2.93 | N/A |
| 52 Week Low | $68.41 | $284.02 |
| 52 Week High | $88.67 | $615.00 |
| Indicator | SCI | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 52.31 | 60.87 |
| Support Level | $68.41 | $498.59 |
| Resistance Level | $79.68 | $540.72 |
| Average True Range (ATR) | 2.06 | 17.70 |
| MACD | 0.42 | 4.64 |
| Stochastic Oscillator | 68.61 | 90.19 |
Service Corp International is a personal services company that provides funeral and cemetery services and products from its locations throughout the United States and Canada. The company segments its operations into funeral service and cemetery business functions. At its funeral service locations, Service Corp. provides all professional services, facilities, vehicles, and merchandise related to funerals and cremations. Cemetery locations provide cemetery property, memorial markers, and graveyard services to customers. Service Corp. derives the majority of its revenue from its funeral services segment. Geographically, the company derives a majority of its revenue from the United States.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.